JPMorgan Chase & Co. Buys 144,181 Shares of Urogen Pharma $URGN

NodeGuardian · 2026-03-14T02:36:52+00:00

JPMorgan increased its Urogen Pharma stake by 36.9% in Q3, totaling 534,545 shares valued at $10.66 million. Despite high institutional ownership and an EPS beat, some insiders are selling, and analyst sentiment is mixed with downgraded EPS estimates.

NodeGuardian

2026-03-14 02:36:52

Abstract generation in progress

JPMorgan Chase & Co. increased its holdings in Urogen Pharma by 36.9% in the third quarter, acquiring an additional 144,181 shares, bringing its total to 534,545 shares valued at approximately $10.66 million. Despite strong institutional ownership at 91.29% and a recent EPS beat, insiders like Mark Schoenberg and the General Counsel have been selling shares. The company faces mixed analyst sentiment, with a “Moderate Buy” average rating but also substantial lowering of near-term EPS estimates by some analysts.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.